300294 博雅生物
已收盘 10-09 15:00:00
资讯
新帖
简况
股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》
证券之星 · 10-09 02:12
股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》
博雅生物（300294）披露召开2026年第三次临时股东会的通知，10月08日股价下跌1.87%
证券之星 · 10-08 22:32
博雅生物（300294）披露召开2026年第三次临时股东会的通知，10月08日股价下跌1.87%
博雅生物：公司持续深化战略实现途径
证券之星 · 09-30
博雅生物：公司持续深化战略实现途径
博雅生物：致力于成为国内乃至世界一流血液制品企业
证券之星 · 09-30
博雅生物：致力于成为国内乃至世界一流血液制品企业
股市必读：博雅生物（300294）9月23日董秘有最新回复
证券之星 · 09-24
股市必读：博雅生物（300294）9月23日董秘有最新回复
博雅生物：以做优做强主业、提升经营质量作为市值管理的核心措施
证券之星 · 09-23
博雅生物：以做优做强主业、提升经营质量作为市值管理的核心措施
博雅生物：截至目前，公司暂无回购、大股东增持等事项
证券之星 · 09-18
博雅生物：截至目前，公司暂无回购、大股东增持等事项
股市必读：博雅生物（300294）9月17日董秘有最新回复
证券之星 · 09-18
股市必读：博雅生物（300294）9月17日董秘有最新回复
博雅生物：以18.2亿元收购绿十字香港控股有限公司100%股权
证券之星 · 09-17
博雅生物：以18.2亿元收购绿十字香港控股有限公司100%股权
博雅生物：坚持深耕主业，聚焦营销、研发、国际化、血浆等核心业务领域
证券之星 · 09-17
博雅生物：坚持深耕主业，聚焦营销、研发、国际化、血浆等核心业务领域
股市必读：博雅生物（300294）9月14日董秘有最新回复
证券之星 · 09-15
股市必读：博雅生物（300294）9月14日董秘有最新回复
公司问答丨博雅生物：截至目前 公司尚未有重组类产品上市
格隆汇 · 09-14
公司问答丨博雅生物：截至目前 公司尚未有重组类产品上市
股市必读：博雅生物新发布《北京大成律师事务所关于公司2026年第二次临时股东会的法律意见书》
证券之星 · 09-11
股市必读：博雅生物新发布《北京大成律师事务所关于公司2026年第二次临时股东会的法律意见书》
股市必读：博雅生物（300294）9月8日董秘有最新回复
证券之星 · 09-09
股市必读：博雅生物（300294）9月8日董秘有最新回复
博雅生物：公司始终围绕战略目标，聚焦营销、研发、国际化、血浆等核心业务领域，提升综合竞争力
证券之星 · 09-08
博雅生物：公司始终围绕战略目标，聚焦营销、研发、国际化、血浆等核心业务领域，提升综合竞争力
博雅生物：公司2026年8月31日含信用账户合并名册的股东人数为31,857户
证券之星 · 09-08
博雅生物：公司2026年8月31日含信用账户合并名册的股东人数为31,857户
股市必读：博雅生物（300294）9月4日董秘有最新回复
证券之星 · 09-07
股市必读：博雅生物（300294）9月4日董秘有最新回复
博雅生物：经营业绩较上年同期下降
证券之星 · 09-04
博雅生物：经营业绩较上年同期下降
博雅生物：持续深化战略实现途径
证券之星 · 09-04
博雅生物：持续深化战略实现途径
股市必读：博雅生物（300294）8月31日董秘有最新回复
证券之星 · 09-01
股市必读：博雅生物（300294）8月31日董秘有最新回复
加载更多
公司概况
公司名称：
华润博雅生物制药集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-03-08
主营业务：
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、凝血因子。公司获得了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格：
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":14.88,"timestamp":1791529416000,"preClose":14.66,"halted":0,"volume":6347800,"delay":0,"changeRate":0.015,"floatShares":504000000,"shares":504000000,"eps":-0.1219,"marketStatus":"已收盘","change":0.22,"latestTime":"10-09 15:00:00","open":14.69,"high":14.91,"low":14.44,"amount":93485400,"amplitude":0.0321,"askPrice":14.89,"askSize":282,"bidPrice":14.88,"bidSize":221,"shortable":0,"etf":0,"ttmEps":-0.1219,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.66,"symbolType":"stock","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":16.13,"lowLimit":13.19,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":0.99,"roa":"--","roe":"0.69%","epsLYR":0.22,"committee":-0.03222,"marketValue":7503000000,"turnoverRate":0.0126,"status":0,"floatMarketCap":7503000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2674279004","title":"股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674279004","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674279004?lang=zh_cn&edition=full","pubTime":"2026-10-09 02:12","pubTimestamp":1791483134,"startTime":"0","endTime":"0","summary":"公司公告汇总公司第八届董事会第二十三次会议决议公告华润博雅生物制药集团股份有限公司于2026年10月8日召开第八届董事会第二十三次会议，审议通过《关于补选第八届董事会非独立董事的议案》，同意补选李宁女士为非独立董事候选人，该事项尚需提交公司2026年第三次临时股东会审议；同时审议通过《关于提请召开公司2026年第三次临时股东会的议案》，会议定于2026年10月29日召开，股权登记日为2026年10月22日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673003013","title":"博雅生物（300294）披露召开2026年第三次临时股东会的通知，10月08日股价下跌1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673003013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673003013?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:32","pubTimestamp":1791469937,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，博雅生物报收于14.66元，较前一交易日下跌1.87%，最新总市值为73.92亿元。近日，华润博雅生物制药集团股份有限公司发布《关于召开公司2026年第三次临时股东会的通知》。公告显示，公司将于2026年10月29日召开2026年第三次临时股东会，会议由公司董事会召集，采取现场投票与网络投票相结合的方式。股权登记日为2026年10月22日，审议事项包括补选第八届董事会非独立董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800034678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671542272","title":"博雅生物：公司持续深化战略实现途径","url":"https://stock-news.laohu8.com/highlight/detail?id=2671542272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671542272?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:51","pubTimestamp":1790758286,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司认为股价持续低迷的原因是什么？对此公司具体采取了什么措施？博雅生物回复：您好，感谢您对本公司的关注。公司股价受宏观经济、行业政策、市场环境等多重因素影响，敬请投资者理性看待市场波动，审慎决策，注意投资风险。公司持续深化战略实现途径，围绕营销、研发、国际化、采浆等方面细化关键举措，坚持以深耕主业、提升盈利质量夯实内在价值根基，同时严格履行信息披露义务。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000026345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671272544","title":"博雅生物：致力于成为国内乃至世界一流血液制品企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2671272544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671272544?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:51","pubTimestamp":1790758277,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否有考虑将博雅转让给更懂得经营它的平台运营，如中国生物，如海尔集团博雅生物回复：您好，感谢您对本公司的关注。控股股东在战略管理、组织优化、人才引进、风险管理及政府资源的嫁接等各方面，给予了公司极大的支持与赋能，为公司长远、稳定发展奠定了坚实的基础。公司持续深化战略实现途径，围绕营销、研发、国际化、采浆等方面细化关键举措，致力于成为国内乃至世界一流血液制品企业。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000026342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143878","title":"股市必读：博雅生物（300294）9月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669143878?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:46","pubTimestamp":1790185577,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，博雅生物报收于14.72元，下跌0.94%，换手率0.73%，成交量3.68万手，成交额5473.38万元。董秘最新回复投资者： 贵公司对于市值管理有什么优秀经验，可以跟股东分享一下吗？公司股价受宏观经济、行业政策、市场环境等多重因素影响，敬请投资者理性看待市场波动，审慎决策，注意投资风险。当日关注点交易信息汇总：9月23日主力资金净流出632.24万元，占总成交额11.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400002164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669101780","title":"博雅生物：以做优做强主业、提升经营质量作为市值管理的核心措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2669101780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669101780?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:15","pubTimestamp":1790154923,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司对于市值管理有什么优秀经验，可以跟股东分享一下吗？博雅生物回复：您好，感谢您对本公司的关注。公司股价受宏观经济、行业政策、市场环境等多重因素影响，敬请投资者理性看待市场波动，审慎决策，注意投资风险。公司将市值管理作为一项长期性、系统性、战略性工作持续推进，以做优做强主业、提升经营质量作为市值管理的核心措施，促进公司健康可持续发展。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300029282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668925061","title":"博雅生物：截至目前，公司暂无回购、大股东增持等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2668925061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668925061?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:51","pubTimestamp":1789735907,"startTime":"0","endTime":"0","summary":"另外十七条还规定“市值形势持续低迷时，采取回购、大股东增持等方式，增强投资者信心，维护市值稳定”，请问公司如何定义“持续低迷”?当下公司股价连续下跌若干年，股价破净，请问是否符合公司定义的“持续低迷”？截至目前，公司暂无回购、大股东增持等事项，后续如有相关安排，公司将严格按照规定履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800035040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668992309","title":"股市必读：博雅生物（300294）9月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2668992309","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668992309?lang=zh_cn&edition=full","pubTime":"2026-09-18 00:50","pubTimestamp":1789663824,"startTime":"0","endTime":"0","summary":"截至2026年9月17日收盘，博雅生物报收于14.1元，上涨0.71%，换手率0.56%，成交量2.82万手，成交额3969.59万元。董秘最新回复投资者： 请问博雅的高管是否都是在华润体系内任命的？交易信息汇总资金流向9月17日主力资金净流出87.48万元，占总成交额2.2%；游资资金净流出74.23万元，占总成交额1.87%；散户资金净流入161.71万元，占总成交额4.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800000431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963242","title":"博雅生物：以18.2亿元收购绿十字香港控股有限公司100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963242","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668963242?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:39","pubTimestamp":1789637966,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物09月17日在投资者关系平台上答复投资者关心的问题。2024年7月17日，公司与韩国GC Corp.及其他股东正式签署《股份购买协议》，以18.2亿元自有资金受让绿十字香港控股有限公司100%股权，实现对境内核心血液制品主体绿十字（中国）生物制品有限公司的间接收购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700027685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668203963","title":"博雅生物：坚持深耕主业，聚焦营销、研发、国际化、血浆等核心业务领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2668203963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668203963?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:39","pubTimestamp":1789637952,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问博雅的高管是否都是在华润体系内任命的？他山之石可以攻玉，这5年来，友商们的市值管理水平远超博雅生物，为何不考虑高薪聘请友商的高管来管理博雅？博雅生物回复：您好，感谢您对本公司的关注及建议。公司已搭建完善且运行成熟的战略决策、经营管理体系，将坚持深耕主业，聚焦营销、研发、国际化、血浆等核心业务领域，提升盈利质量夯实内在价值根基。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700027669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667671660","title":"股市必读：博雅生物（300294）9月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2667671660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667671660?lang=zh_cn&edition=full","pubTime":"2026-09-15 00:53","pubTimestamp":1789404790,"startTime":"0","endTime":"0","summary":"截至2026年9月14日收盘，博雅生物报收于14.2元，上涨0.5%，换手率0.68%，成交量3.44万手，成交额4878.37万元。董秘最新回复投资者： 公司是否有考虑引进国药或者莱仕的高管指导维护市值董秘： 您好，感谢您对本公司的关注。截至目前，公司尚未有重组类产品上市。当日关注点交易信息汇总：9月14日主力资金净流出97.18万元，占总成交额1.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500000524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667217654","title":"公司问答丨博雅生物：截至目前 公司尚未有重组类产品上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667217654","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667217654?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:39","pubTimestamp":1789378759,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666909895","title":"股市必读：博雅生物新发布《北京大成律师事务所关于公司2026年第二次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666909895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666909895?lang=zh_cn&edition=full","pubTime":"2026-09-11 02:00","pubTimestamp":1789063249,"startTime":"0","endTime":"0","summary":"公司公告汇总：2026年第二次临时股东会审议通过补选冯四洲、林昂为第八届董事会独立董事的议案。公司公告汇总北京大成律师事务所关于公司2026年第二次临时股东会的法律意见书北京大成律师事务所确认华润博雅生物制药集团股份有限公司2026年第二次临时股东会的召集、召开程序合法，出席会议人员及召集人资格合法有效，表决程序及结果符合相关法律法规和公司章程规定；会议审议通过补选冯四洲、林昂为公司第八届董事会独立董事的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374003","title":"股市必读：博雅生物（300294）9月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374003?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:21","pubTimestamp":1788888078,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，博雅生物报收于15.13元，上涨3.91%，换手率1.68%，成交量8.45万手，成交额1.26亿元。董秘最新回复投资者： 你好，想问一下，跌了这么久，现在的股东人数是多。经查询中国证券登记结算有限责任公司的数据，公司2026年8月31日含信用账户合并名册的股东人数为31,857户。当日关注点交易信息汇总：9月8日主力资金净流入1075.45万元，占总成交额8.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326740","title":"博雅生物：公司始终围绕战略目标，聚焦营销、研发、国际化、血浆等核心业务领域，提升综合竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326740?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:24","pubTimestamp":1788859453,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：博雅生物在同行业中有什么竞争优势？博雅生物回复：您好，感谢您对本公司的关注。公司始终围绕战略目标，聚焦营销、研发、国际化、血浆等核心业务领域，提升综合竞争力。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800026871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665832672","title":"博雅生物：公司2026年8月31日含信用账户合并名册的股东人数为31,857户","url":"https://stock-news.laohu8.com/highlight/detail?id=2665832672","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665832672?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:24","pubTimestamp":1788859452,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，想问一下，跌了这么久，现在的股东人数是多。博雅生物回复：您好，感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据，公司2026年8月31日含信用账户合并名册的股东人数为31,857户。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800026870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665362213","title":"股市必读：博雅生物（300294）9月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2665362213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665362213?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:03","pubTimestamp":1788714194,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，博雅生物报收于14.47元，上涨0.35%，换手率0.89%，成交量4.5万手，成交额6545.36万元。董秘最新回复投资者： 请问管理层血制品为什么越卖越亏？公司经营业绩较上年同期下降主要受区域联盟集采、医保控费、增值税政策调整及市场竞争加剧等影响。当日关注点交易信息汇总：9月4日博雅生物主力资金净流出579.42万元，占总成交额8.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664337003","title":"博雅生物：经营业绩较上年同期下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2664337003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664337003?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:42","pubTimestamp":1788514925,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问管理层血制品为什么越卖越亏？不是战略产品吗？博雅生物回复：您好，感谢您对本公司的关注。公司经营业绩较上年同期下降主要受区域联盟集采、医保控费、增值税政策调整及市场竞争加剧等影响。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333094","title":"博雅生物：持续深化战略实现途径","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333094?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:42","pubTimestamp":1788514925,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物09月04日在投资者关系平台上答复投资者关心的问题。公司持续深化战略实现途径，围绕营销、研发、国际化、采浆等方面细化关键举措，致力于成为国内乃至世界一流血液制品企业。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000008","title":"股市必读：博雅生物（300294）8月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664000008?lang=zh_cn&edition=full","pubTime":"2026-09-01 03:26","pubTimestamp":1788204373,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，博雅生物报收于14.69元，下跌1.54%，换手率0.89%，成交量4.49万手，成交额6611.59万元。董秘最新回复投资者： 公司的业绩为什么越来越差，以后有什么举措来改善董秘： 您好，感谢您对本公司的关注。自2025年以来，血液制品行业面临多重政策叠加带来的阶段性压力。投资者： 博雅生物经过华润5年的赋能，从160亿以上市值，到现在不足80亿。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100004037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791571156292,"stockEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0081},{"period":"3month","weight":0.0122},{"period":"6month","weight":-0.2071},{"period":"1year","weight":-0.4028},{"period":"ytd","weight":-0.3386}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31989人(较上一季度增加0.41%)","perCapita":"15763股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、凝血因子。公司获得了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}